2024
155-OR: Genetic Variation and Time to Progression in TN10 (Teplizumab)
MICHALEK D, ONENGUT-GUMUSCU S, CHEN W, BRUSKO T, STECK A, GOTTLIEB P, ORAM R, KRISCHER J, PARIKH H, REDONDO M, HEROLD K, RICH S. 155-OR: Genetic Variation and Time to Progression in TN10 (Teplizumab). Diabetes 2024, 73 DOI: 10.2337/db24-155-or.Peer-Reviewed Original ResearchGenome-wide analysisTime to progressionInfluence time to progressionPolygenic scoresDrug response genesNon-HLA variantsGenome-wide arrayRandomized phase 2 clinical trialAssociated with time to progressionPhase 2 clinical trialProgression to type 1 diabetesCox proportional hazards regression modelsGenetic variationTn10Proportional hazards regression modelsGenetic modifiersHigh-risk participantsHazards regression modelsLociType 1 diabetesNovel pathwaysTeplizumab groupTeplizumabVitamin DImmune-relevant
2019
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. New England Journal Of Medicine 2019, 381: 603-613. PMID: 31180194, PMCID: PMC6776880, DOI: 10.1056/nejmoa1902226.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntibodies, Monoclonal, HumanizedCD3 ComplexChildDiabetes Mellitus, Type 1Disease ProgressionDouble-Blind MethodExanthemaFemaleGlucose Tolerance TestHLA-DR3 AntigenHLA-DR4 AntigenHumansLymphocyte CountLymphopeniaMaleMiddle AgedProportional Hazards ModelsT-LymphocytesYoung AdultConceptsType 1 diabetesClinical type 1 diabetesTeplizumab groupPlacebo groupOral glucose tolerance testInsulin-producing beta cellsDouble-blind trialChronic autoimmune diseaseGlucose tolerance testRelatives of patientsRate of diagnosisHigh-risk participantsTransient lymphopeniaAdverse eventsHazard ratioHLA-DR3HLA-DR4Median timeClinical progressionAutoimmune diseasesExogenous insulinCD3 antibodyT cellsTeplizumabClinical disease